Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease Dave SinghSimon LeaAlexander G. Mathioudakis Leading Article 03 November 2021 Pages: 1821 - 1830
The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density Anna C. van der BurghCatherine E. de KeyserBruno H. Stricker Review Article Open access 01 November 2021 Pages: 1831 - 1858
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience? Eduardo MyslerValderilio Feijó AzevedoLaurent Peyrin-Biroulet Review Article Open access 27 October 2021 Pages: 1859 - 1879
Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective Pekka KurkiSean BarryElena Wolff-Holz Original Research Article Open access 01 October 2021 Pages: 1881 - 1896
Interchangeability of Biosimilars: Overcoming the Final Hurdles Liese BarbierArnold G. Vulto Commentary 02 November 2021 Pages: 1897 - 1903
Avatrombopag: A Review in Thrombocytopenia Anthony Markham Adis Drug Evaluation Open access 28 October 2021 Pages: 1905 - 1913
Donafenib: First Approval Susan J. KeamSean Duggan AdisInsight Report 30 September 2021 Pages: 1915 - 1920
Disitamab Vedotin: First Approval Emma D. Deeks AdisInsight Report 18 October 2021 Pages: 1929 - 1935
Correction to: Contezolid: First Approval Sheridan M. Hoy Correction 23 October 2021 Pages: 1945 - 1945
Correction to: Sotorasib: First Approval Hannah A. Blair Correction Open access 23 October 2021 Pages: 1947 - 1947
Correction to: REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study Christian Domingo Ribas Teresa Carrillo Díazthe REDES Study Group Correction Open access 21 October 2021 Pages: 1949 - 1951
